

Chunxia Su

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7962716/publications.pdf>

Version: 2024-02-01

15
papers

380
citations

1039406

9
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

591
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1625-1631.	2.0	9
2	Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 115-123.	0.9	19
3	Three-dimensionally printed navigational template: a promising guiding approach for lung biopsy. <i>Translational Lung Cancer Research</i> , 2022, 11, 393-403.	1.3	3
4	HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies. <i>Frontiers in Oncology</i> , 2022, 12, 860313.	1.3	12
5	Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. <i>Lung Cancer</i> , 2022, 167, 25-33.	0.9	9
6	Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 353-360.	0.8	9
7	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	1.3	6
8	The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1149-1158.	1.3	17
9	HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. <i>Lung Cancer</i> , 2020, 147, 99-105.	0.9	21
10	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1 or BRAF. <i>Cancer Medicine</i> , 2019, 8, 2858-2866.	1.3	59
11	Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3486-3494.	3.2	56
12	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations – Still a daily challenge. <i>European Journal of Cancer</i> , 2017, 83, 266-278.	1.3	22
13	Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 2558-2567.	0.8	70
14	Osimertinib for EGFR T790M positive non-small cell lung cancer – making it happen, turning good idea into great results. <i>Translational Cancer Research</i> , 2017, 6, S494-S497.	0.4	0
15	Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients. <i>Translational Oncology</i> , 2014, 7, 341-348.	1.7	68